Switzerland· 58038002
Myozyme, Poudre pour solution à diluer pour perfusion
A alglucosidase alfa product containing alglucosidasum alfa, registered in Switzerland by Sanofi-Aventis (Suisse) SA and dispensed under Swissmedic category A. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Alglucosidase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB07 (alglucosidase alfa), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Alglucosidase alfa · ATC A16AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alglucosidase alfa costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- Switzerland: $1240.40 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Alglucosidase alfa · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$1240.40
The record
At a glance
Swissmedic (Switzerland)- Active substance
- alglucosidasum alfa
- Manufacturer
- Sanofi-Aventis (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- A16AB07
- ATC class
- Alglucosidase alfa
- Defined daily dose
- 0.1 g, P
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alglucosidase alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAlglucosidase alfa 1.15g/500ml infusion bagsSpecial Order
- CzechiaMYOZYMESanofi B.V., Amsterdam
- FinlandMyozymeOrifarm Oy
- SpainMYOZYME 50 MG POLVO CONCENTRADO PARA SOLUCION PARA PERFUSIONSanofi B.V.
- FranceMYOZYME 50 mg, poudre pour solution à diluer pour perfusionSANOFI (PAYS-BAS)
- IrelandMyozyme 50 mg powder for concentrate for solution for infusionSanofi B.V.
- IcelandMyozymeGenzyme Europe B.V.
- NetherlandsMyozyme, poeder voor concentraat voor oplossing voor i.v. infusie 50 mgGenzyme Europe BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Myozyme
- Liechtenstein · Myozyme
- Norway · Myozyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/631afcb1-2738-411f-b7cd-a4d7bd2011f2 GET /v1/drugs/631afcb1-2738-411f-b7cd-a4d7bd2011f2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about alglucosidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.